Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia

NCT06602934 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-01-02
Last updated
2026-06-04

Condition(s) studied

Hospital Acquired Pneumonia (HAP)Cardiovascular and Respiratory Disease

Investigational drug(s) / intervention(s)

Blood samplesOropharyngeal swabsECGCardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration

Blood samples: Four blood samples will be taken outside standard care for groups A, B, C and D: at inclusion, M6 and M18 (only at inclusion for group C).

Oropharyngeal swabs: An oropharyngeal swab will be taken to analyze patients\' upper airway microbiome at inclusion, M6 and M18.

ECG: Performed at inclusion, M6 and M18

Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration: Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration: These tests will be performed consecutively for 2 hours at inclusion M6 and M18. These tests will be performed to assess respiratory and cardiac function.

Study summary

The HOMI-LUNG - HAP study is part of the HOMI-LUNG project, funded by the Horizon Europe program. The "HOMI-LUNG" project is an international, interdisciplinary project that aims to better understand the causal links between respiratory tract infections (i.e. pneumonia) and the progression of cardiovascular disease. More specifically, the project aims to quantify the burden of cardiovascular disease after pneumonia and assess patients; acceptability of long-term health alterations, as well as to define pneumonia endotypes with distinct pathobiological mechanisms associated with exacerbation of cardiovascular disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: Group A (patients with acute cardiac disease) * Male or female * Hospitalized for acute coronary syndrome for less than 7 days. * Informed consent from the patient * Person insured under a health insurance scheme Group B (patients with chronic cardiovascular disease) * Male or female, * Undergoing coronary artery by-pass surgery * Hospitalized in intensive care unit for \&gt; 12 hours * Informed consent from the patient * Person insured under a health insurance scheme Group C (patients at risk of CVRD without chronic cardiovascular disease) * Male or female, * Familial high levels of cholesterol or triglycerides * With no personal history of CVRD, with a recent negative cardiac exercise test (last test inferior to 12 months) * Follow-up for lipid abnormalities at high risk of CVRD events * Informed consent from the patient * Person insured under a health insurance scheme Group D (patients with HAP) * Male or female * With one or more risk factors for CVD among: Age ≥ 65 years old Smoking, Abnormal lipidic levels, High blood pressure, Obesity, Diabetes mellitus, Chronic kidney disease * Cured from mechanically ventilated HAP during the current hospitalization * Informed consent from the patient or relatives * Person insured under a health insurance scheme Exclusion Criteria: * Groups A, B, C and D * Age \<80 years old * Immunosuppression pre-existing to the index hospitalisation, defined as lymphopenia; 500 elements/mm3, haematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion, or anti-graft rejection drug. * Pregnant women, breastfeeding women. * Adults under guardianship or trusteeship. * Low probability of survival at day 28. o Groups A, B, C * Community-acquired pneumonia or Hospital-acquired pneumonia within the last year.

Primary outcome measure(s)

  • Major adverse cardiovascular events (MACE) — 6 months
    Major adverse cardiovascular events (MACE) at 6 months

Trial sites (5)

FacilityCityRegionStatus
Angers University Hospital Angers France Not Yet Recruiting
Nantes University Hospital Nantes France Recruiting
Rennes University Hospital Rennes France Not Yet Recruiting
Rouen University Hospital Rouen France Not Yet Recruiting
Toulouse University Hospital Toulouse France Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06602934 on ClinicalTrials.gov ↗ ← All trials in France